IL-6 may facilitate ovarian cancer progression through additional pathways, such as IL-6/JAK2/STAT3, IL-6/STAT3/HIF-1α, and mtDNA/toll-like receptor (TLR9)/NF-κB/IL-6 [215]. Here, STAT3 is linked to ovarian carcinoma.